Natixis Invests $333,000 in Novartis AG (NVS) Stock

Natixis purchased a new stake in shares of Novartis AG (NYSE:NVS) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 4,421 shares of the company’s stock, valued at approximately $333,000.

Other hedge funds have also made changes to their positions in the company. Cox Capital Co LLC acquired a new position in Novartis during the second quarter valued at approximately $1,399,000. Commerzbank Aktiengesellschaft FI lifted its position in Novartis by 13.7% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 48,425 shares of the company’s stock valued at $3,658,000 after buying an additional 5,823 shares in the last quarter. Neuburgh Advisers LLC lifted its position in Novartis by 13.0% during the second quarter. Neuburgh Advisers LLC now owns 22,984 shares of the company’s stock valued at $1,736,000 after buying an additional 2,652 shares in the last quarter. Fosun International Ltd acquired a new position in Novartis during the second quarter valued at approximately $468,000. Finally, Country Trust Bank lifted its position in Novartis by 23.7% during the second quarter. Country Trust Bank now owns 470,358 shares of the company’s stock valued at $35,531,000 after buying an additional 90,168 shares in the last quarter. 10.95% of the stock is currently owned by hedge funds and other institutional investors.

NYSE NVS opened at $85.46 on Monday. Novartis AG has a 52 week low of $72.30 and a 52 week high of $94.19. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.89 and a current ratio of 1.15. The firm has a market cap of $198.05 billion, a PE ratio of 17.77, a PEG ratio of 1.79 and a beta of 0.85.

Novartis (NYSE:NVS) last posted its earnings results on Wednesday, July 18th. The company reported $1.29 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.02. Novartis had a net margin of 27.06% and a return on equity of 16.05%. The business had revenue of $13.16 billion for the quarter, compared to analysts’ expectations of $12.93 billion. During the same period in the previous year, the company posted $1.22 earnings per share. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. equities research analysts anticipate that Novartis AG will post 5.17 earnings per share for the current year.

A number of brokerages have weighed in on NVS. Zacks Investment Research raised shares of Novartis from a “hold” rating to a “buy” rating and set a $95.00 price target on the stock in a research report on Tuesday, September 18th. BNP Paribas raised shares of Novartis from an “underperform” rating to a “neutral” rating in a research report on Tuesday, September 11th. ValuEngine raised shares of Novartis from a “sell” rating to a “hold” rating in a research report on Wednesday, September 12th. Exane BNP Paribas raised shares of Novartis from an “underperform” rating to a “neutral” rating in a research report on Tuesday, September 11th. Finally, Citigroup raised shares of Novartis from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 11th. Eleven investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Novartis has an average rating of “Hold” and an average target price of $86.90.

In other news, major shareholder Bioventures Ltd Novartis sold 30,600 shares of the business’s stock in a transaction on Monday, July 23rd. The shares were sold at an average price of $4.25, for a total transaction of $130,050.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last three months, insiders have sold 81,322 shares of company stock worth $290,796. Corporate insiders own 0.01% of the company’s stock.

Novartis Profile

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

Further Reading: What do I need to know about analyst ratings?

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply